CME Presentations




  • Ana Barac, MD, PhD

    Ana Barac, MD, PhD

    Ana Barac, MD, PhD

    Associate Professor of Medicine

    Ana Barac, MD, PhD, is an Associate Professor of Medicine at Georgetown University and the Director of the MedStar Heart and Vascular Institute's Cardio-Oncology program. Her research interests focus on the mechanisms, diagnosis, and treatment of cardiovascular complications of cancer therapies. Dr. Barac is internationally recognized for her work on cardiovascular health in patients with cancer. She is the founding Chair of the American College of Cardiology (ACC) Cardio-Oncology Council and serves as co-director of the ACC's annual Live Course on Advancing Cardiovascular Care. Furthermore, Dr. Barac is the cardiology principal investigator for the SAFE-HEaRt trial, investigating safety of HER2 targeted therapies in patients with HER2 positive breast cancer and reduced cardiac function.
  • William Wierda, MD, PhD

    William Wierda, MD, PhD

    William Wierda, MD, PhD

    Professor and Medical Director, Department of Leukemia

    William Wierda, MD, PhD, is Professor and Medical Director for the Department of Leukemia and Executive Medical Director for Leukemia, Lymphoma and Stem Cell Transplant at The University of Texas MD Anderson Cancer Center. Dr. Wierda's research focuses on identifying immunology and immunotherapy strategies for hematologic malignancies, particularly chronic lymphocytic leukemia (CLL). He has served as principal investigator or co-investigator for numerous clinical trials, lectured nationally and internationally, and published on clinical and translational aspects of CLL and drug development. Furthermore, Dr. Wierda serves as Chair and Value Pathways Task Force Member for the NCCN CLL/SLL/Hairy Cell Leukemia Panel and is a member of the American College of Physicians and other organizations.

CME Information

Global Logo PQH Logo
All Abuzz About CLL: Exploring Fixed-Duration Regimens and Cardiotoxicity Management
This activity is jointly provided by Global Education Group and PlatformQ Health Education, LLC, in collaboration with CLL Society, Inc.


This activity is supported an educational grant from Genentech, a member of the Roche Group and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.


Friday, September 16, 2022 from 3:00 – 4:00pm ET


The intended audience for this activity are hematologic oncologists, hematologists, cardiologists, cardio‐oncologists, oncology advanced practice providers (NPs and PAs), oncology nurses, and other clinicians involved in the management of patients with CLL.


The emergence of effective therapeutic combinations and the promise of fixed duration treatments holds the potential of improved long-term outcomes and quality of life for patients with chronic lymphocytic leukemia (CLL). While patients and providers alike have expressed a preference for time-limited therapies, a number of questions remain around clinical decision-making, including how to select patients for these therapies, and once on treatment, how to anticipate and address treatment-related adverse events.

Clinicians may be unaware of findings from late‐stage trials examining these combinations and may be hesitant to use certain therapies based on associated toxicity profiles. To help clarify misconceptions related to adverse events and ensure appropriate cardio‐oncology care when warranted, please join a panel of hematology/oncology and cardio-oncology experts to review the most up-to-date data on the care of CLL. Hear from a patient on their account of receiving upfront targeted therapy and their experience through decision-making. Panelists will share strategies to select the right upfront therapy as part of patient-centered care that maximizes long-term outcomes, ensures patient quality of life, and anticipates and manages side effects.


After completing this activity, the participant should be better able to:
  • Review the late-stage clinical data and ongoing trials evaluating fixed-duration regimens in CLL
  • Discuss patient preferences for fixed-duration therapy and strategies for patient counseling on appropriate treatment selection
  • Evaluate long-term and real-world data to maximize patient outcomes
  • Assess the current evidence-based guidelines and best practices for appropriate cardiovascular toxicity management across the cardio-oncology team
  • Facilitate patient-centered care through accounts of real-world patient experiences


This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.


Global Education Group designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

This educational activity for 1.0 contact hour is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.


This activity should take approximately 60 minutes to complete.


In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a minimum score of 70% on the post-test.


Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.


There is no fee for this educational activity.


Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:
Name of Faculty or Presenter Reported Financial Relationship
Ana Barac, MD, PhD, FACC, FAHA Professor of Medicine Georgetown University Director of Cardio-Oncology Program Medstar Heart and Vascular Institute Medstar Washington Hospital Center Nothing to disclose
William G. Wierda, MD, PhD Department of Leukemia Division of Cancer Medicine The University of Texas MD Anderson Cancer Center Contracted Research: Abbvie, Acerta Pharma, AstraZeneca, Bristol Myers Squibb (Juno & Celgene), Cyclacel, Genentech, Gilead Sciences, GlaxoSmithKline, Janssen, KITE Pharma, Lilly, Loxo Oncology, Inc., Miragen, Novartis, Oncternal Therapeutics, Inc., Pharmacyclics LLC, Sunesis, and Xencor
The planners and managers have the following relevant financial relationships with ineligible companies:
Name of Planner or Manager Reported Financial Relationship
Rhys Williams, MSN, FNP-C, RN Nothing to disclose
Lindsay Borvansky Nothing to disclose
Andrea Funk Nothing to disclose
Liddy Knight Nothing to disclose
Ashley Cann Nothing to disclose
Lauren Sinclair Nothing to disclose
Tariqa Ackbarali Nothing to disclose
Vandana Gupta Nothing to disclose
Stephanie Puccio Nothing to disclose
Garrett Covington – Patient Participant Nothing to disclose


This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health Education, LLC do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


Accreditation Support: For information about the accreditation of this program, please contact Global at 303-395-1782 or

Technical Support: For any technical issues or issues with your CME Certificate, please contact OMedLive or CardioCareLive at 877-394-1306 or at or